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0-protein-coupled receptor kinases. /3-Adrenergic receptors are proto-
types of the many C-protein-coupled receptors. Activation and inactiva-
tion of these receptors are regulated by multiple mechanisms which can
affect either their function or their expression. The most obvious changes
of such receptor systems are induced by activation of the receptors
themselves by their respective agonists, and this process is called receptor
desensitization. One of these mechanisms of desensitization is due to the
actions of specific receptor kinases, termed the 0-protein-coupled recep-
tor kinases (ORKs). These kinases specifically phosphorylate only the
agonist-occupied form of such receptors. This phosphorylation is then
followed by binding of inhibitor proteins, called arrestins, to the receptors.
Binding of arrestins results in displacement of the 0-proteins from the
receptors and hence causes uncoupling of receptors and 0-proteins.
Recent data indicate that the function and subeellular distribution of
ORKs is itself subject to regulation. Various mechanisms have evolved to
anchor the different ORKs to the plasma membrane. In addition, recent
data indicate that 0RKs can also associate with intracellular membranes
where they may exert as yet unknown functions. A pathophysiological role
for ORKs can be inferred from recent studies on heart failure as well as
the ohservation that chronic treatment with various agonists or antagonists
for 0-protein-coupled receptors results in alterations of ORK expression.
G-protein-coupled receptors and their mechanisms
of activation
The family of 0-protein-coupled receptors contains several
hundred members for diverse agonists including light and olfac-
tory stimuli, large proteohormones and small neurotransmitters
and hormones such as serotonin and epinephrine [1—3]. Such
receptor systems contain three components, the receptors them-
selves, an intermediate GTP-binding protein (0-protein) and the
effectors, which may be enzymes, such as adenylyl cyclase, or ion
channels. Activation of these receptors is transmitted via the
0-proteins to the effectors and results in alterations of second
messenger concentrations, for example cAMP, in the cell interior.
0-protein-coupled receptors share a common structure that is
characterized by seven transmembrane a-helices, an extracellular
N-terminus and an intracellular C-terminus. In most instances the
seven a-helices form a hydrophilic pocket that serves as the
binding pocket for their ligands. Exceptions are the receptors for
large proteohormones that contain an extended N-terminus for
ligand binding.
Occupancy of the receptors is thought to induce a conforma-
tional change into their active form. Very little is known about the
nature of this conformational change. A model proposed by
Oliveira et al [4] suggests that ligand binding results in charge
neutralization within the transmcmbrane helices and thereby
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allows for their lateral rearrangement. Such rearrangement must
then alter the conformation of the intracellular loops which are
responsible for coupling to 0-proteins. Experiments with chimeric
a-//3-adrenergic receptors [5] have shown that—at least in these
receptors—the third intracellular loop is the region which deter-
mines the specificity of 0-protein-coupling. In addition, the
second extracellular loop and the beginning of the C-terminus are
thought to participate in 0-protein coupling. This can be inferred
from a large data of mutagenesis and peptide competition exper-
iments. For example, Konig et al [6] have shown that peptides
corresponding to these three regions in the light receptor rhodop-
sin, which couples to the G-protein transduein, can act in a
synergistic manner to disrupt rhodopsin/transducin binding. Sim-
ilar multisite contacts have been established using peptides de-
rived from f3-adrenergic receptors to study coupling to their
0-protein G [7].
The substitution of a single amino acid in the third loop of the
a,0-adrenergic receptor by any other amino acid results in
constitutively active receptors, that is, receptors that are active
even in the absence of agonist [8]. As a cnnsequence, it appears
that the receptors are conformationally restrained in their inactive
state, and that receptor activation relieves this restraint. Alterna-
tively, it may be concluded that the receptors can assume multiple
conformations, and that only one of these is inactive while the
others exhibit various degrees of constitutive activity.
The G-proteins, which serve as signal transducers, are com-
posed of a 0TP-binding a-subunit and a tightly bound fry-subunit
complex [9]. There are multiple isoforms of each of these
subunits. Experiments using anti-sense oligonucleotide injections
to knock out the expression of 0-protein subunits suggest that (at
least in some cases) 0-proteins serving specific functions are
composed of defined subunits [10—13]. However, biochemical
reconstitution experiments have so far shown only limited speci-
ficity of these subunits [14, 15]. Thus, specificity may reside not so
much in the properties of the individual subunits, but in their
assembly to functional 0-protein/receptor systems in the cell.
Receptor-mediated activation of 0-proteins results in the ex-
change of 0DP for GTP by the G-protein a-subunit, followed by
dissociation of the activated a-subunit from the f3y-complex. Both
the a-subunit and the /3y-complex can transmit signals to effectors
[16, 17]. Major signals transmitted via the a-subunits include the
stimulation (as) and inhibition (a1) of adenylyl cyclase and
stimulation of phospholipase C (aq). The f3y-suhunits can either
stimulate or inhibit certain isoforms of adenylyl cyclase and can
activate phospholipase C and potassium channels. In addition,
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Fig. 1. Schematic alignment of the mammalian
GRKs. GRK4 exists in two N-terminal splice
variants.
they serve as membrane anchors for several cytosolic proteins
which thereby become components of such receptor systems.
Desensitization of G-protein-coupled receptors
The signals generated in response to receptor stimulation are
subject to a variety of regulatory mechanisms. The most important
role of these mechanisms is to dampen the response to repeated
or prolonged stimuli, a process which is called receptor desensi-
tization [18, 191. Receptor desensitization can be mediated by
several molecular mechanisms, which may be operative to varying
extents in different cells and different receptor systems.
Two basic patterns of receptor desensitization can be distin-
guished: a reduction in receptor function and a reduction in
receptor expression.
Receptor expression. A reduction in receptor expression becomes
visible only after about 30 to 60 minutes of receptor stimulation. The
mechanisms involved are ill-understood [20, 211. They appear to
include (a) agonist-induced degradation of the receptor protein that
may require prior internalization of the receptors and transfer to
lysosomes, and (b) reductions of the receptor mRNA-levels,
which have been proposed to occur either as a result of reduced
transcription [22] or a reduced half-life of the mRNA [23].
Receptor function. Much more is known about agonist-induced
loss of receptor function. These are changes which occur within
seconds after receptor stimulation and are mediated primarily by
uncoupling receptors from their G-proteins. Such uncoupling can
be brought about by the action of two types of kinases: (i) specific
kinases whose only known function is to phosphorylate G-protein-
coupled receptors, and which are therefore called the G-protein-
coupled receptor kinases (GRK5); or (ii) by the effector kinases of
such receptor systems, protein kinases A and C. A third agonist-
induced process is called receptor sequestration and probably
represents the removal of receptors from the cell surface into
endosomes. In these endosomcs the receptors may either become
dephosphorylated and then be recycled to the cell surface,
or—upon prolonged receptor stimulation—they may be degraded
[24—26].
Data obtained for the 32-adrenergic receptor system in the
human A431 carcinoma cell line give some indication about the
kinetics of these mechanisms: I3ARK-mediated desensitization
occurred with a half-life of <15 seconds, PKA-mediated desensi-
tization followed with a half-life of two minutes, and receptor
sequestration proceeded with a half-life of 10 minutes [27—29].
However, these values may be quite different in other cells, since
they must depend on the number of receptors present on the cell
surface as well as on the expression levels of the kinases and
possibly other proteins involved in these processes.
The family of G-protein-coupled receptor kinases
The most specific and rapid mechanism desensitizing G-pro-
tein-coupled receptors is triggered via their phosphorylation by
G-protein-coupled receptor kinases (GRKs). Phosphorylation of
receptors by GRKs is triggered by agonist-activation of the
receptors. This phosphorylation increases the affinity of the
receptors towards a family of cytosolic inhibitor proteins, termed
arrestins, which bind to the phosphorylated receptors and thereby
cause uncoupling of receptors and G-proteins. GRK-mediated
desensitization seems to be most important at fairly high agonist
concentrations. Physiologically, such high agonist concentrations
occur in synapses, and in fact GRKs as well as arrestins are
concentrated at postsynaptic sites [30, 31].
Of the six cloned members of the family of GRKs [32] only two
have been shown to be involved in the regulation of j3-adrenergic
receptor function, even though all six appear to be capable of
phosphorylating the receptors in vitro. These two are termed
f3-adrenergic receptor kinases-1 and 2 (I3ARK-1 and 2, which
correspond to GRK2 and 3 in the GRK-terminology).
Membrane attachment of GRKs
All of the GRKs cloned so far share the same architecture (Fig.
1). A central catalytic domain is flanked by an N- and a C-terminal
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domain. All three domains are quite well conserved among the
different GRKs. Palczewski and coworkers could demonstrate
that an antibody directed against the extreme N-terminus of
rhodopsin kinase blocked phosphorylation of rhodopsin but not
that of a synthetic peptide substrate [33]. No other studies on the
functional role of the N-terminus have been reported (but see
below).
The C-terminal domains are involved in membrane localization
which is necessary for effective substrate phosphorylation. GRKs
1, 4, 5 and 6 also posscss potential autophosphorylation sites in
this region [34]. The modes of membrane attachment vary be-
tween the different GRKs:
- Rhodopsin kinase (=GRK1) is isoprenylated and carboxy-
methylated at the very C-terminus.
- The C-termini of ARK1 and 2 (GRK2 and 3) bind both to G
protein fry-subunits and to certain phospholipids.
- GRK5 can also bind phospholipids at its C-terminus, but this
C-terminus is not homologous to that of /3ARK1 or 2.
- The C-terminus of GRK6 is palmitoylated via a cysteine
thioester.
- The membrane localization signal for GRK4 is unknown.
The domain responsible for membrane targeting in /3ARK1 and
2 has received considerable attention because it contains a
pleckstrin homology (PH) domain [35]. This domain has been
identified in a wide variety of proteins involved mainly in intra-
cellular signaling and cytoskeletal architecture. They are separate
folding units consisting of about 120 amino acids. It is now clear
that the PH domain of f3ARK1 overlaps with the f3y-binding
domain [36]; the PH domain alone binds fry-subunits only weakly.
However, this does not seem to be a general property since some
PH domains apparently do not bind fry-subunits at all [37]. In
vitro, I3ARK1 shows a weak selectivity for certain 13y-combina-
tions [15]; the physiological importance of this specificity is
unknown.
Many PH domains, including those of f3ARK1, also bind quite
selectively to phosphatidylinositol-3,4-bisphosphate (PIP2) [38,
39] without gross conformational change [40]. The PIP2 binding
site is spatially distinct from the fry-binding site [41]. Possibly
important for the regulation of I3ARK function (see below) is the
observation that certain isoforms of PKC can bind to several PH
domains [42, 43]. The PH domains of ARK1 or 2 were not
included in these experiments.
The subcellular location of GRKs 4, 5, and 6 has not been
thoroughly investigated. For rhodopsin kinase, /3ARK1 and
I3ARK2 it has been demonstrated that, upon stimulation of
receptors, the kinases translocate from a cytosolic to a membrane
fraction. The molecular process of translocation is, in the case of
rhodopsin kinase, not understood. In the case of f3ARK1 and
ARK2 it is believed that free G protein f3y-subunits, liberated
from their corresponding a-subunit by receptor activation, "trap"
the enzyme at the membrane and thus near its prospective
substrate. Binding of the ARKs to PIP2 may aid in the translo-
cation process [39], but others have observed inhibitory effects of
PIP2 on pARK-mediated receptor phosphorylation [44, 45]. Thus,
the role of membrane lipids in anchoring f3ARKs to the mem-
brane needs further clarification.
Regulation of membrane attachement of GRK
Depending on the kind of GRK several modes of regulation of
membrane attachment are conceivable. They depend on the
membrane anchors discussed above. The most obvious one among
them is the translocation of GRKs by agonist stimulation of the
receptor [46—48]. The other anchors are probably also regulated,
but very little is known about the possibility of such regulation.
Kunapuli, Gurevich and Benovic [49] investigated phospholipid
regulation of GRK5. The autophosphorylation is increased by
lipids. This effect depends on the hydrophobic character of the
molecule and not on the kind of head group. Both a GST fusion
protein of the GRK5 C-terminus and a GRK5 mutant that cannot
autophosphorylate inhibit the autophosphoiylation of the wild
type GRK5. The mutant has the same enzymatic activity towards
casein, a soluble substrate, but a reduced activity versus f3-adren-
ergic receptor or rhodopsin which hints at enhanced membrane
binding after autophosphorylation. The physiological relevance
and phosphorylation state of GRK5 in vivo still remain unclear.
The situtation is somewhat different for f3ARKI and I3ARK2.
The role of G5 [50, 51] and phospholipids [39, 41, 44, 45] for their
membrane attachment and activation in vitro is known, but how
this is regulated in vivo has still to be elucidated.
Two recent papers discuss the regulation of DARK by PKC.
Chuang, LeVine and De Blasi [52] reported that PKC mediated
phosphorylation and activation of DARK in vivo and in vitro. Our
own data [53] showed that the activation is due to enhanced
translocation of I3ARK to the membrane. Thus, the increased
activity after phosphorylation of /3ARK by PKC was only seen
when a membrane-bound substrate like rhodopsin was used, while
the activity of DARK towards a soluble peptide was even de-
creased after PKC-phosphorylation. Second, in intact cells PKC
appears to induce a translocation of DARK from the cytosol to the
membrane. The PKC-phosphorylation site could be mapped to
the C-terminus of the /3ARK, the region critical for membrane
binding. These data indicate a heterologous regulation of I3ARK
via PKC-activating signalling pathways. Whether this phosphoiy-
lation-induced membrane attachement is due to increased or
phospholipid binding or other mechanisms is unknown.
3ARK1 displays a variety of intracellular locations
Until recently, DARK was described as a soluble, cytosolic
enzyme that transiently translocates to the cytoplasmic side of the
plasma membrane when the receptor is occupied by an agonist
[46—48, 54]. As mentioned above, recent data indicate that the
interaction of the C-terminal domain of 13ARK with fry-subunits
of G proteins may help to target the kinase to the plasma
membrane and to increase its activity towards receptors. How-
ever, !3ARK subeellular location appears to be a more complex
issue, since a significant amount of total DARK activity ('35 to
50%) is associated with internal microsomal membranes in a
variety of tissues and cell lines [55, 56]. Subcellular fractionation
studies as well as indirect immunofluorescence and immunogold
electron microscopy localization in cultured cells have confirmed
the association of PARK with microsomal structures "in situ" [55].
The same is observed in cells stably transfected with /3ARK 1
(Ruiz-Gómez et al, unpublished observations). Therefore, several
DARK pools (microsome-bound, plasma membrane-bound and
cytosolic) would exist inside the cell, thus raising the functional
roles of this kinase and the mechanisms that regulate its subcel-
lular distribution and activation.
A key issue to be addressed is the nature of the anchor(s) of
DARK in the internal membranes and the domain of the kinase
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involved in the interaction. Cell-free association experiments have
indicated that DARK peripherally associates with a protein com-
ponent of the microsomal membranes by means of electrostatic
interactions [55]. Since heterotrimeric G proteins are also present
in intracellular membranes [57], microsomal /3y-subunits were
obvious candidates for participating in I3ARK binding. In fact, a
funtional modulation of PARK activity by endogenous G proteins
can be detected in microsomal membranes [58]. However, it
appears that the main factor responsible for J3ARK association
with internal membranes is an additional, currently unidentified
anchoring protein(s) that would interact with a new targeting
domain located in the N-terminal region of DARK [58]. The
existence of different anchoring proteins emerges as a general
mechanism for regulating the subcellular distribution and activity
ofavariety of protein kinases [59]. In addition to the identification
of the PARK anchor in internal membranes, another question to
be solved is the possible functional role of /3ARK in such an
intracellular location. One possibility is that it is related to its
translocation and receptor regulation function in the plasma
membranes. In this regard, a transient increase in microsomal
DARK activity has been reported in neonatal rat liver coincident
ith a process of p-adrenergic receptor desensitization [56]. Alterna-
tively, or in addition, microsomal PARK may serve other unknown
cellular functions, which may be related to those of heterotrimeric
G proteins also present in intracellular membranes.
In summary, the regulation of PARK activity and subcellular
distribution will likely involve multiple interactions with G protein
subunits, phospholipids, different domains of G protein-coupled
receptors and possibly additional anchoring proteins [44, 58]. The
unveiling of the mechanisms governing such interactions could
shed new light on our understanding of receptor regulation
processes.
Pathophysiological roles for GRKs
Changes in the expression levels and/or activity of the modula-
tory proteins of the GRKs and 13-arrestin families may affect the
rate and extent of desensitization of p-adrenergic and other G
protein-coupled receptors. Given the numerous physiological
roles of G protein-coupled receptors, it might be expected that
alterations in their mechanisms of regulation and desensitization
could underlie a variety of human pathologies.
Although very little is known about the mechanisms of regula-
tion of the GRKs and J3-arrestin genes, very recent data support
the notion that alterations in desensitization mechanisms may
indeed operate in pathophysiological situations. For instance, the
activity and mRNA levels of PARKI are increased in failing
hearts, thus probably contributing to the marked dysfunction of
the p-adrenergic systems in these patients and to the progression
of heart failure [60, 61]. Consistently, transgenic animals overex-
pressing I3ARK-l in cardiac tissue show alterations in their heart
response to catecholamines [62]. On the contrary, reduced 13-ad-
renergic receptor activation by means of chronic antagonist
treatment decreases pARK-like activity in porcine heart [63].
Expression of 13ARKs 1 and 2 appears also to be modulated in
activated lymphocytes [64] and in the locus coeruleus after
chronic morphine treatment [65]. An active role for /3-adrenergic
receptor regulatory mechanisms in peripheral tissues has been
reported in the neonatal rat immediately after birth, a physiolog-
ical situation characterized by a dramatic but transient increase in
plasma catecholamines [561. It is tempting to speculate that these
mechanisms of receptor regulation may play a role in limiting the
extent, kind and time frame of catecholamine actions during this
period of life, and possibly also in other psychological or patho-
logical situations in which tissues are exposed to high circulating
or local levels of messengers, such as in some cases of hyperten-
sion. The increasing availability of research tools should facilitate
the identification of alterations in ORKs and 13-arrestin proteins
in different pathophysiological circumstances.
Acknowledgments
Work in the authors' laboratories is supported by grants from the
European Commission (to M.J.L. and F.M.), the Deutsche Forschungs-
gemeinschaft, the Fonds der Chemischen Industrie (to M.J.L.), the
DGICYT and the Fundación Ramón Areces (to F.M.)
Reprint requests to Prof M.J. Lohse, Department of Phannacology,
Versbacher Stra/3e 9, D-97074 Wurzburg, Germany. E-mail: lohse@toxi.uni-
wuerzburg. de
References
1. Ki-io HG: Rhodopsin, photoreceptor of the rod cell. An emerg-
ing pattern for structure and function. J Biol Chem 267:1—4, 1992
2. BOEGE F, NEUMANN E, HELMREICH EJM: Structural heterogeneity
of membrane receptors and GTP-binding proteins and its func-
tional consequences for signal transduction. Eur J Biochem 199:1—
15, 1991
3. D0HLMAN HG, THORNER J, CAR0N MG, LEFKOWITZ RJ: Model
systems for the study of seven-transmembrane-segment receptors.
Annu Rev Biochem 60:653—88, 1991
4. Oiiviw. L, PAIVA ACM, SANDER C, VRIEND G: A common step for
signal transduction in G protein-coupled receptors. Trends Pharmacol
Sci 15:170—172, 1994
5. KOBILKA BK, KOBILKA TS, DANIEL K, REGAN JW, CARON MG,
LEFKOWITZ RJ: Chimeric a2-,f32-adrenergic receptors: Delineation of
domains involved in effector coupling and ligand binding specificity.
Science 240:1310—1316, 1988
6. KONIG B, ARENDT A, MCDOWELL JH, KAFILERT M, HARGRAvE PA,
HOFMANN KP: Three cytoplasmic loops of rhodopsin interact with
transducin. Proc Nati Acad Sci USA 86:6878—6882, 1989
7. MUNCH G, DEES C, HEKMAN M, PALM D: Multisite contacts involved
in coupling of the /3-adrenergic receptor with the stimulatory guanine-
nucleotide-binding protein. Structural and functional studies by /3-re-
ceptor-site-specific synthetic peptides. Eur J Biochem 198:357—364,
1991
8. KJELSBERG MA, COTECCHIA 5, OSTROWSKI J, CARON MG, LEFKOWITZ
RJ: Constitutive activation of the a1-adrenergic receptor by all amino
acid substitutions at a single site. Evidence for a region which
constrains receptor activation. J Biol Chem 267:1430—1433, 1992
9. HEPLER JR, GILMAN AG: G proteins. Trends Biochem Sci 17:383—387,
1992
10. KALKBRENNER F, DEGTIAR VE, SCHENKER M, BRENDEL S, ZOBEL A,
HESCHELER J, Wrrn B, SCHULTZ G: Subunit composition of G0
proteins functionally coupling galanin receptors to voltage-gated
calcium channels. EMBO J 14:4728—4737, 1995
11. KLEUSS C, HE5CHELER J, EWEL C, ROSENTHAL W, SCHULTZ 0, Wn-nG
B: Assignment of 0-protein subtypes to specific receptors inducing
inhibition of calcium currents. Nature 353:43—48, 1991
12. KLEUSS C, SCHERUEL H, HESCHELER J, SCHULTZ G, Wirno B:
Different /3-subunits determine 0-protein interaction with transmem-
brane receptors. Nature 358:424—426, 1992
13. KLEUSS C, SCHERUBL H, HESCHELER J, SCHULTZ G, WIrnG B:
Selectivity in signal transduction determined by y subunits of hetero-
trimeric 0 proteins. Science 259:832—834, 1993
14. UEDA N, IrIGUEZ-LLUHi JA, LEE E, SMRCKA AV, ROBISHAW JD,
GILMAN AG: G protein I3ysubunits.JBiol Chem 269:4388—4395,1994
Lohse et al: G-protein-coupled receptor kinases 1051
15. MULLER S, HEKMAN M, LOHSE Mi: Specific enhancement of /3-ad-
renergic receptor kinase activity by defined G-protein 13 and
subunits. Proc Nati Acad Sci USA 90:10439—10443, 1993
16. BIRNBAUMER L: Receptor-to-effector signalling through G proteins:
Roles for 3y dimers as well as a subunits. Cell 71:1069—1072, 1992
17. MULLER 5, LOHSE MJ: The role of G-protein f3y subunits in signal
transduction. Biochem Soc Trans 23:141—148, 1995
18. HAUSDORFF WP, CARON MG, LEFKowrrz RJ: Turning off the signal:
Desensitization of /3-adrenergic receptor function. FASEB J 4:2881—
2889, 1990
19. LOHSE MJ: Molecular mechanisms of membrane receptor desensiti-
zation. Biochim Biophys Acta 1179:171—188, 1993
20. COLLINS S, LOUSE MJ, O'DowD B, CARON MG, LEFKOWITZ RJ:
Structure and regulation of G protein-coupled receptors: The
/32-adrenergic receptor as a model. Vitamins and Hormone 46:1—39,
1991
21. HADCOCK JR, MALBON CC: Regulation of receptor expression by
agonists: Transcriptional and post-transcriptional controls. Trends
Neurosci 14:242—247, 1991
22. HOs0DA K, FITZGERALD LR, VAIDYA VA, FEUSSNER GK, FISHMAN
PH, DUMAN RS: Regulation of /32-adrenergic recpetor mRNA and
gene transcription in rat C6 glioma cells: Effects of agonist,
forskolin, and protein synthesis inhibition. Mol Pharmacol 48:206—
211, 1995
23. HADCOCK JR, WANG H-Y, MALBON CC: Agonist-induced destabili-
zation of /3-adrenergic receptor mRNA. Attenuation of glucocorti-
coid-induced up-regulation of /3-adrenergic receptors. J Biol Chem
264:19928—19933, 1989
24. KURZ JB, PERKINS JP: Isoproterenol-initiated /3-adrenergic receptor
diacytosis in cultured cells. Mol Pharmacol 41:375—381, 1992
25. VON ZASTROW M, KOBILKA BK: Ligand-regulated internalization and
recycling of human /32-adrenergic receptors between the plasma
membrane and endosomes containing transferrin receptors. J Biol
Chem 267:3530—3538, 1992
26. PIPPIG S, ANDEXINGER S, LOHSE Mi: Sequestration and recycling of
/32-adrenergic receptors permit receptor resensitization. Mol Pharma-
col 47:666—676, 1995
27. LOHSE MJ, BENOVIC JL, CARON MG, LEFKOWITZ RJ: Multiple
pathways of rapid /32-adrenergic receptor desensitization. J Biol Chem
265:3202—3209, 1990
28. LOHSE MJ: Quantification of receptor desensitization by an opera-
tional model of agonism. JBiol Chem 265:3210—3211, 1990
29. ROTH NS, CAMPBELL PT, CARON MG, LEFKOWITZ Ri, LOUSE Mi:
Comparative rates of desensitization of /3-adrenergic receptors by the
/3-adrenergic receptor kinase and the cyclic AMP-dependent protein
kinase. Proc NatlAcad Sci USA 88:6201—6204, 1991
30. ARRIZA JL, DAWSON TM, SIMERLY RB, MARTIN U, CARON MG,
SNYDER SH, LEFKOWITZ Ri: The G-protein-coupled receptor kinases
/3ARK1 and I3ARK2 are widely distributed at synapses in rat brain. J
Neurosci 12:4045—4055, 1992
31. ATITRAMADAL H, ARRZA JL, A0KI C, DAWSON TM, CODINA i,
KWATRA MM, SNYDER SH, CARON MG, LEFKOWITZ Ri: /3-Arrestin2,
a novel member of the arrestin//3-arrestin gene family. J Biol Chem
267:17882—17890, 1992
32. INGLESE i, FREEDMAN NJ, KOCH WJ, LEFKOWITZ Ri: Structure and
mechanism of the G protein-coupled receptor kinases. J Biol Chem
268:23735—23738, 1993
33. PALCZEWSKI K, BUCZYLKO J, LEBIODA L, CRABB iW, POLANS AS:
Identification of the N-terminal region in rhodopsin kinase involved in
its interaction with rhodopsin. J Biol Chem 268:6004—6013, 1993
34. PREMONT RT, INGLESE J, LEFKOWITZ Ri: Protein kinases that phos-
phorylate activated G protein-coupled receptors. FASEB J 9:175—182,
1995
35. MUSACCHIO A, GIBSON T, RICE P, THOMPSON J, SARASTE M: The PH
domain: A common piece in the structural patchwork of signalling
proteins. Trends Biochem Sci 18:343—348, 1993
36. TOIJHARA K, INGLESE J, PITCHER iA, SHAW G, LEFKOWITZ RJ:
Binding of G protein fry-subunits to pleckstrin homology domains. J
Biol Chem 269:10217—10220, 1994
37. MAHADEVAN D, THANKI N, SINGH J, MCPHIE P, ZANGRILLI D, WANG
L-M, GUERRENS C, LEVINE H III, HUMBLET C, SALDANHA J, GUTKIND
iS, NAGMABADI-HASKE T: Structural studies on the PH domains of
Dbl, SosI, IRS-i, and /3ARK1 and their differential binding to
subunits. Biochemistty 34:9111—9117, 1995
38. HARLAN JE, HAJDUK PJ, YooN HS, FESIK SW: Pleckstrin homology
domains bind to phosphatidylinositol-4,5-hisphosphate. Nature 371:
168—170, 1994
39. PITCHER J, TOUHARA K, PAYNE ES, LEFKOWITZ Ri: Pleckstrin homol-
ogy domain-mediated membrane association and activation of the
/3-adrenergic receptor kinase requires coordinate interaction with
subunits and lipid. JBiol Chem 270:11707—11710, 1995
40. HYVONEN M, MAClAS MJ, NILGES M, OSCHKJNAT H, SARASTE M,
WILMANNS M: Structure of the binding Site for inositol phosphates in
a PH domain. EMBO J 14:4676—4685, 1995
41. TOUHARA K, KOCH Wi, HAWES BE, LEFKOWITZ Ri: Mutational
analysis of the pleckstrin homology domain of the /3-adrenergic
receptor kinase. Differential effects on G and phosphatidylinositol
4,5-bisphosphate binding. J Biol Chem 270:17000—17005, 1995
42. K0NIsHI H, KURODA S, KIKKAWA U: The pleckstrin homology domain
of RAC protein kinase associates with the regulatory domain of
protein kinase C . Biochem Biophys Res Commun 205:1770—1775,
1994
43. YAo L, KAWAKAMI Y, KAWAKAMI T: The pleckstrin homology domain
of Bruton tyrosine kinase interacts with protein kinase C. Proc Natl
Acad Sci USA 91:9175—9179, 1994
44. DEBBURMAN 5K, PTASIENSKI J, BOETTICHER E, LOMASNEY JW,
BENOVIC JL, HOSEY MM: Lipid-mediated regulation of G protein-
coupled receptor kinases 2 and 3. J Biol Chem 270:5742—5747, 1995
45. ONORATO JJ, GILLIS ME, Lw Y, BENOVIC JL, RuoHo AE: The
f3-adrenergic receptor kinase (GRK2) is regulated by phospholipids. J
Biol Chem 270:21346—21353, 1995
46. STRASSER RH, BENOVIC iL, CARON MG, LEFKOWITZ RJ: /3-Agonist-
and prostaglandin E1-induced translocation of the /3-adrenergic re-
ceptor kinase: Evidence that the kinase may act on multiple adenylate
cyclase-coupled receptors. Proc Nail Acad Sci USA 83:6362— 6366,
1986
47. MAYOR F JR, BENOVIC JL, CARON MG, LEFKOWITZ RJ: Somatostatin
induces translocation of the /3-adrenergic receptor kinase and desen-
sitizes somatostatin receptors in S49 lymphonia cells. J Biol Chem
262:6488—6471, 1987
48. GARCIA-HIGUERA I, MAYOR F JR: Rapid agonist-induced beta-adren-
ergic receptor kinase translocation in C6 glioma cells. FEBS Lett
302:61—64, 1992
49. KUNAPULI P. GUREVICH VV, BENOVIC JL: Phospholipid-stimulated
autophosphorylation activates the G protein-coupled receptor kinase
GRK5. J Biol Chem 269:10209—10212, 1994
50. HAGA K, HAGA T: Activation by G protein /ly subunits of agonists- or
light-dependent phosphorylation of muscarinic acetylcholine recep-
tors and rhodopsin. J Biol Chem 267:2222—2227, 1992
51. PITCHER iA, INGLESE J, HIGGINS JB, ARRIZA JL, CASEY PJ, KIM CM,
BENOVIC JL, KWATRA MM, CARON MG, LEFKOWITZ Ri: Role of fry
subunits of G proteins in targeting the /3-adrenergic receptor kinase to
membrane-bound receptors. Science 257:1264—1267, 1992
52. CHUANG 'VF, LEVINE H III, DE BLASI A: Phospholylation and
activation of /3-adrenergic receptor kinase by protein kinase C. J Biol
Chem 270:18660—18665, 1995
53. WINSTEL R, FREUND S, KRASEL C, HOPPE E, LOHSE MJ: Protein
kinase cross-talk: Membrane targeting of the f3-adrenergic receptor
kinase by protein kinase C. Proc NatI Acad Sci USA (in press)
54. CHUANG TI, SALLESE M, AMBROSINI G, PARRUTI G, DE BLASI A:
High expression of /3-adrenergic receptor kinase in human peripheral
blood leukozytes. J Biol Chem 267:6886—6892, 1992
55. GARCIA-HIGUERA I, PENELA P, MURGA C, EGEA G, BONAY P,
BENOVIC iL, MAYOR F JR: Association of the regulatory /3-adrenergic
receptor kinase with rat liver microsomal membranes. J Biol Chem
269:1348—1355, 1994
56. GARCfA-HIGVERA I, MAYOR F JE: Rapid desensitization of neonatal
rat liver /3-adrenergic receptors. A role for /3-adrenergic receptor
kinase. J Clin Invest 93:937—943, 1994
57. NUOFFER C, BALCH WE: GTPases: Multifunctional molecular
switches regulating vesicular traffic. Annu Rev Biochem 63:949—990,
1994
58. MURGA C, RUIZ-GOMEZ A, GARCIA-HIGUERA I, KIM CM, BENOVIC
JL, MAYOR F iR: High affinity binding of /3-adrenergic receptor kinase
1052 Lohse et a!: G-protein-coupled receptor kinases
to microsomal membranes. Modulation of the activity of bound kinase
by heterotrimeric G protein activation. JBiol Chem 271:985—994, 1996
59. MOCHLY-ROSEN D: Localization of protein kinases by anchoring
proteins: A theme in signal transduction. Science 268:247—25 1, 1995
60. UNGERER M, BOHM M, ELCE JS, ERDMANN E, LOUSE MJ: Altered
expression of f3-adrenergic receptor kinase and 1-adrenergic recep-
tors in the failing human heart. Circulation 87:454—463, 1993
61. ENGELHARDT S, BOUM M, ERDMANN E, LOUSE MJ: Analysis of
/3-adrenergic receptor mRNA-levels in human ventricular biopsies by
RT-PCR: Progressive reduction of 131-adrenergic receptor mRNA in
heart failure. JAm Coil Cardiol (in press)
62. KOCH WJ, ROCKMAN HA, SAMAMA P, HAMILTON R, BOND RA,
MILANO CA, LEFKOWITZ RJ: Cardiac function in mice overexpressing
the /3-adrenergic receptor kinase or a PARK inhibitor. Science
268:1350—1353, 1995
63. PING P, GELZER-BELL R, ROTH DA, KIEL D, INSEL PA, HAMMOND
HK: Reduced /3-adrenergic receptor activation decreases G-protein
expression and /3-adrenergic receptor kinase activity in porcine heart.
J Clin Invest 95:1271—1280, 1995
64. Da BLASI A, PARRUTI G, SALLESE Mr Regulation of G protein-
coupled receptor kinase subtypes in activated T lymphocytes. Selective
increase of /3-adrenergic receptor kinase 1 and 2. J Clin Invest
95:203—210, 1995
65. TERWILLINGER RZ, ORrlz I, GUITART X, Nasmeit EJ: Chronic mor-
phine administration increases /3-adrenergic receptor kinase (/3ARK)
levels in the rat locus coeruleus. J Neurochem 63:1983—1986, 1994
